US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.
Bharti Jayshankar December 28, 2024: A recent research reveals that certain symptoms precede a diagnosis of multiple sclerosis (MS) in pediatric patients. The.
HQ Team September 3, 2023: The jury is still out on which virus causes chronic fatigue syndrome, its diagnosis, the treatment options, and.
HQ Team August 17, 2023: A study on mice has produced a vaccine for Epstein-Barr virus, which is linked to a 32-fold higher.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com